RU2663123C2
(ru)
|
2010-11-30 |
2018-08-01 |
Чугаи Сейяку Кабусики Кайся |
Индуцирующий цитотоксичность терапевтический агент
|
RU2605390C2
(ru)
|
2011-08-23 |
2016-12-20 |
Рош Гликарт Аг |
Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
BR112015007120A2
(pt)
|
2012-10-08 |
2017-12-12 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
EP2943511B1
(en)
|
2013-01-14 |
2019-08-07 |
Xencor, Inc. |
Novel heterodimeric proteins
|
TWI682941B
(zh)
|
2013-02-01 |
2020-01-21 |
美商再生元醫藥公司 |
含嵌合恆定區之抗體
|
KR101833602B1
(ko)
|
2013-02-26 |
2018-02-28 |
로슈 글리카트 아게 |
이중특이적 t 세포 활성화 항원 결합 분자
|
RU2015140915A
(ru)
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
|
WO2014145907A1
(en)
|
2013-03-15 |
2014-09-18 |
Xencor, Inc. |
Targeting t cells with heterodimeric proteins
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res (Munich) Gmbh |
Moléculas de unión para bcma y cd3
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
KR101815265B1
(ko)
*
|
2013-06-20 |
2018-01-04 |
한올바이오파마주식회사 |
FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
|
CA2918795A1
(en)
|
2013-07-25 |
2015-01-29 |
Cytomx Therapeutics, Inc. |
Multispecific antibodies, multispecific activatable antibodies and methods of using the same
|
CN110156893B
(zh)
|
2013-12-17 |
2023-03-03 |
基因泰克公司 |
抗cd3抗体及使用方法
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
US10106623B2
(en)
|
2014-02-12 |
2018-10-23 |
Michael Uhlin |
Bispecific antibodies for use in stem cell transplantation
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
SG10202008629XA
(en)
|
2014-03-28 |
2020-10-29 |
Xencor Inc |
Bispecific antibodies that bind to cd38 and cd3
|
PL3126383T3
(pl)
|
2014-04-03 |
2019-08-30 |
Igm Biosciences, Inc. |
Zmodyfikowany łańcuch J
|
NZ724710A
(en)
|
2014-04-07 |
2024-02-23 |
Chugai Pharmaceutical Co Ltd |
Immunoactivating antigen-binding molecule
|
BR112016026299A2
(pt)
*
|
2014-05-13 |
2018-02-20 |
Chugai Seiyaku Kabushiki Kaisha |
molécula de ligação ao antígeno redirecionado à célula t para células tendo função de imunossupressão
|
CN107108738A
(zh)
|
2014-07-25 |
2017-08-29 |
西托姆克斯治疗公司 |
抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法
|
MA40510A
(fr)
|
2014-08-04 |
2017-06-14 |
Hoffmann La Roche |
Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
EP3191520B1
(en)
|
2014-09-12 |
2020-01-01 |
Genentech, Inc. |
Anti-cll-1 antibodies and immunoconjugates
|
EP3201227A4
(en)
|
2014-09-29 |
2018-04-18 |
Duke University |
Bispecific molecules comprising an hiv-1 envelope targeting arm
|
WO2016077720A1
(en)
*
|
2014-11-14 |
2016-05-19 |
Protein One, Llc |
Binding agents and uses thereof
|
PL3221359T3
(pl)
*
|
2014-11-17 |
2020-11-16 |
Regeneron Pharmaceuticals, Inc. |
Sposoby leczenia nowotworów przy użyciu dwuswoistego przeciwciała CD3XCD20
|
ES2835823T3
(es)
|
2014-11-20 |
2021-06-23 |
Hoffmann La Roche |
Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T para CD3 y para el receptor de folato 1 (FolR1) y antagonistas de la unión al eje de PD-1
|
SI3223605T1
(sl)
*
|
2014-11-24 |
2021-03-31 |
Regeneron Pharmaceuticals, Inc. |
Nehumane živali, ki izražajo humaniziran CD3 kompleks
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
JP2017536830A
(ja)
|
2014-11-26 |
2017-12-14 |
ゼンコー・インコーポレイテッドXencor、 Inc. |
Cd3及びcd38に結合するヘテロ二量体抗体
|
IL252480B2
(en)
|
2014-11-26 |
2023-12-01 |
Xencor Inc |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
EP3227336B1
(en)
|
2014-12-05 |
2019-07-03 |
F.Hoffmann-La Roche Ag |
Anti-cd79b antibodies and methods of use
|
EP3029137B1
(en)
|
2014-12-06 |
2019-01-02 |
GEMoaB Monoclonals GmbH |
Genetic modified pluri- or multipotent stem cells and uses thereof
|
US20170058043A1
(en)
*
|
2014-12-06 |
2017-03-02 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Bispecific antibody for cancer immunotherapy
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
US10544220B2
(en)
*
|
2015-01-08 |
2020-01-28 |
Genmab A/S |
Bispecific antibodies against CD3 and CD20
|
HUE054642T2
(hu)
|
2015-03-04 |
2021-09-28 |
Igm Biosciences Inc |
CD20 kötõ molekulák és ezek felhasználása
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
WO2016149698A2
(en)
|
2015-03-19 |
2016-09-22 |
Duke University |
Hiv-1 neutralizing antibodies and uses thereof (v3 antibodies)
|
AU2016232693B2
(en)
|
2015-03-19 |
2021-08-12 |
Duke University |
HIV-1 neutralizing antibodies and uses thereof
|
WO2016149695A1
(en)
|
2015-03-19 |
2016-09-22 |
Duke University |
HIV-1 NEUTRALIZING ANTIBODIES AND USES THEREOF (CD4bs ANTIBODIES)
|
US11071783B2
(en)
|
2015-03-19 |
2021-07-27 |
Duke University |
HIV-1 neutralizing antibodies and uses thereof
|
AU2016242866B2
(en)
|
2015-03-30 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Heavy chain constant regions with reduced binding to FC gamma receptors
|
AU2016262368B2
(en)
*
|
2015-05-08 |
2019-05-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
EA039429B1
(ru)
*
|
2015-05-13 |
2022-01-26 |
Ридженерон Фармасьютикалз, Инк. |
Способы лечения опухолей с применением биспецифического антитела cd3xcd20
|
KR101997241B1
(ko)
|
2015-05-21 |
2019-07-09 |
하푼 테라퓨틱스, 인크. |
삼중특이성 결합 단백질 및 사용 방법
|
CN107646038B
(zh)
*
|
2015-05-28 |
2021-08-20 |
基因泰克公司 |
用于检测抗cd3同二聚体的基于细胞的测定
|
CN104931699A
(zh)
*
|
2015-05-29 |
2015-09-23 |
北京海思特临床检验所有限公司 |
骨髓涂片异常淋巴细胞染色试剂盒及其使用方法
|
AU2016274767B2
(en)
*
|
2015-06-09 |
2022-05-19 |
Eureka Therapeutics, Inc. |
T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA
|
TW201718647A
(zh)
|
2015-06-16 |
2017-06-01 |
建南德克公司 |
抗-cll-1抗體及使用方法
|
AR105026A1
(es)
|
2015-06-16 |
2017-08-30 |
Genentech Inc |
ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO
|
LT3313879T
(lt)
|
2015-06-24 |
2022-03-25 |
F. Hoffmann-La Roche Ag |
Antikūnai prieš transferino receptorių su pritaikytu giminingumu
|
EP3319996B1
(en)
*
|
2015-07-09 |
2024-01-03 |
Genmab A/S |
Bispecific and multispecific antibodies and method for isolation of such
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
JOP20160154B1
(ar)
*
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI797060B
(zh)
|
2015-08-04 |
2023-04-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
US11352426B2
(en)
*
|
2015-09-21 |
2022-06-07 |
Aptevo Research And Development Llc |
CD3 binding polypeptides
|
CN108290951B
(zh)
*
|
2015-09-23 |
2022-04-01 |
瑞泽恩制药公司 |
优化抗cd3双特异性抗体和其用途
|
WO2017059380A1
(en)
|
2015-09-30 |
2017-04-06 |
Igm Biosciences, Inc. |
Binding molecules with modified j-chain
|
CN108463472A
(zh)
|
2015-09-30 |
2018-08-28 |
Igm生物科学有限公司 |
具有修饰的j-链的结合分子
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
TWI819458B
(zh)
|
2015-10-02 |
2023-10-21 |
瑞士商赫孚孟拉羅股份公司 |
雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
BR112018000835A2
(pt)
|
2015-10-02 |
2018-09-11 |
Hoffmann La Roche |
molécula, um ou mais polinucleotídeos, um ou mais vetores, célula, método de produção da molécula, composição, uso da molécula, método de tratamento de uma doença e método para induzir a lise de uma célula-alvo
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗lag3抗體及其用途
|
EP3819310A1
(en)
|
2015-10-25 |
2021-05-12 |
Sanofi |
Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
|
WO2017086367A1
(ja)
*
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
|
EP3378488A4
(en)
*
|
2015-11-18 |
2019-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR ENHANCING THE HUMORAL IMMUNE RESPONSE
|
CN106810611A
(zh)
*
|
2015-11-30 |
2017-06-09 |
中国科学院深圳先进技术研究院 |
抗cMet和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
|
CN106810610A
(zh)
*
|
2015-11-30 |
2017-06-09 |
中国科学院深圳先进技术研究院 |
抗EpCAM和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
|
US11623957B2
(en)
|
2015-12-07 |
2023-04-11 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
PL3387015T3
(pl)
|
2015-12-09 |
2022-02-14 |
F. Hoffmann-La Roche Ag |
Przeciwciało anty-CD20 typu II do ograniczania tworzenia przeciwciał przeciwlekowych
|
HUE063377T2
(hu)
|
2015-12-22 |
2024-01-28 |
Regeneron Pharma |
Anti-PD-1 antitestek és bispecifikus anti-CD20/anti-CD3 antitestek kombinációja a rák kezelésére
|
CA3006529A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
CN109073635A
(zh)
*
|
2016-01-25 |
2018-12-21 |
豪夫迈·罗氏有限公司 |
用于测定t细胞依赖性双特异性抗体的方法
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
CA3016424A1
(en)
*
|
2016-03-14 |
2017-09-21 |
Chugai Seiyaku Kabushiki Kaisha |
Cell injury inducing therapeutic drug for use in cancer therapy
|
PE20231511A1
(es)
|
2016-03-22 |
2023-09-26 |
Hoffmann La Roche |
Moleculas biespecificas de celulas t activadas por proteasas que se unen especificamente al receptor 1 de folato (folr1) y cd3
|
MY192090A
(en)
|
2016-04-13 |
2022-07-26 |
Sanofi Sa |
Trispecific and/or trivalent binding proteins
|
CA3015389A1
(en)
|
2016-04-20 |
2017-10-26 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for making antibodies based on use of expression-enhancing loci
|
EP3445780A1
(en)
|
2016-04-20 |
2019-02-27 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for making antibodies based on use of an expression-enhancing locus
|
TWI786044B
(zh)
|
2016-05-13 |
2022-12-11 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
US10544221B2
(en)
*
|
2016-05-20 |
2020-01-28 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
US10100106B2
(en)
|
2016-05-20 |
2018-10-16 |
Harpoon Therapeutics, Inc. |
Single domain serum albumin binding protein
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
EP3464352B1
(en)
*
|
2016-05-27 |
2021-03-24 |
Altor BioScience Corporation |
Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
BR112019022558A2
(pt)
|
2016-06-02 |
2020-05-19 |
Hoffmann La Roche |
anticorpos, métodos para tratar ou retardar a progressão de uma doença proliferativa e para tratar ou retardar a progressão do câncer em um indivíduo, composições farmacêuticas, kit, usos de uma combinação de um anticorpo anti-cd20 e de um anticorpo e invenção
|
IL263542B1
(en)
|
2016-06-14 |
2024-06-01 |
Xencor Inc |
Bispecific antibodies inhibit immunological checkpoint
|
EP3471754A1
(en)
|
2016-06-20 |
2019-04-24 |
Kymab Limited |
Anti-pd-l1 antibodies
|
KR20190053835A
(ko)
*
|
2016-06-21 |
2019-05-20 |
테네오바이오, 인코포레이티드 |
Cd3 결합 항체
|
CN109689692B
(zh)
|
2016-06-22 |
2021-11-12 |
本康生物制药(深圳)有限公司 |
用于肿瘤治疗的双特异性抗体和抗体偶联物及其应用
|
WO2018005706A1
(en)
|
2016-06-28 |
2018-01-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
CN107573416A
(zh)
*
|
2016-06-30 |
2018-01-12 |
中国科学院深圳先进技术研究院 |
抗igf1r和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用
|
CN109789092A
(zh)
|
2016-07-13 |
2019-05-21 |
哈佛学院院长等 |
抗原呈递细胞模拟支架及其制备和使用方法
|
CN106317226B
(zh)
*
|
2016-08-19 |
2017-09-05 |
安源医药科技(上海)有限公司 |
用于构建融合蛋白的连接肽
|
EP3504328A1
(en)
|
2016-08-24 |
2019-07-03 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
DK4050034T3
(da)
|
2016-09-14 |
2024-06-03 |
Teneoone Inc |
Cd3-bindende antistoffer
|
IL265369B2
(en)
|
2016-09-23 |
2024-03-01 |
Regeneron Pharma |
Antibodies against (MUCIN 16) MUC16
|
JP7078609B2
(ja)
|
2016-09-23 |
2022-05-31 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗steap2抗体、抗体-薬物複合体、およびsteap2とcd3を結合する二重特異性抗原結合分子、ならびにそれらの使用
|
ES2897217T3
(es)
|
2016-09-30 |
2022-02-28 |
Hoffmann La Roche |
Anticuerpos biespecíficos frente a p95HER2
|
EP3519436A4
(en)
*
|
2016-09-30 |
2020-09-09 |
Baylor College of Medicine |
TISSUE-ORIENTED ANTIBODY-BASED GENE THERAPY
|
AU2017342559B2
(en)
|
2016-10-14 |
2022-03-24 |
Xencor, Inc. |
Bispecific heterodimeric fusion proteins containing IL-15/IL-15Ralpha Fc-fusion proteins and PD-1 antibody fragments
|
TWI791471B
(zh)
|
2016-11-15 |
2023-02-11 |
美商建南德克公司 |
用於用抗cd20/抗cd3雙特異性抗體進行治療之給藥
|
BR112019010602A2
(pt)
|
2016-11-23 |
2019-12-17 |
Harpoon Therapeutics Inc |
proteínas trispecíficas para psma e métodos de uso
|
WO2018098354A1
(en)
|
2016-11-23 |
2018-05-31 |
Harpoon Therapeutics, Inc. |
Prostate specific membrane antigen binding protein
|
EP4252629A3
(en)
|
2016-12-07 |
2023-12-27 |
Biora Therapeutics, Inc. |
Gastrointestinal tract detection methods, devices and systems
|
SG11201907208XA
(en)
|
2017-02-10 |
2019-09-27 |
Regeneron Pharma |
Radiolabeled anti-lag3 antibodies for immuno-pet imaging
|
KR20240011262A
(ko)
|
2017-02-21 |
2024-01-25 |
리제너론 파아마슈티컬스, 인크. |
폐암의 치료를 위한 항-pd-1 항체
|
US11459394B2
(en)
|
2017-02-24 |
2022-10-04 |
Macrogenics, Inc. |
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
|
WO2018160754A2
(en)
|
2017-02-28 |
2018-09-07 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
EA201892312A1
(ru)
*
|
2017-03-17 |
2019-04-30 |
Санофи |
Триспецифические и/или тривалентные связывающие белки
|
JP7050333B2
(ja)
*
|
2017-03-24 |
2022-04-08 |
全薬工業株式会社 |
抗IgM/B細胞表面抗原二重特異性抗体
|
EP3600416B1
(en)
|
2017-03-30 |
2023-06-07 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
US10730954B2
(en)
|
2017-05-12 |
2020-08-04 |
Harpoon Therapeutics, Inc. |
MSLN targeting trispecific proteins and methods of use
|
US10543271B2
(en)
|
2017-05-12 |
2020-01-28 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
EP3409322A1
(en)
|
2017-06-01 |
2018-12-05 |
F. Hoffmann-La Roche AG |
Treatment method
|
IL271194B1
(en)
|
2017-06-20 |
2024-06-01 |
Teneobio Inc |
Anti-BCMA antibodies containing only heavy chains
|
BR112019026803A2
(pt)
|
2017-06-20 |
2020-06-30 |
Teneoone, Inc. |
anticorpos apenas de cadeia pesada anti-bcma
|
WO2019006472A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
|
JP7265494B2
(ja)
|
2017-07-06 |
2023-04-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
糖タンパク質を作製するための細胞培養方法
|
JP7164596B2
(ja)
*
|
2017-08-28 |
2022-11-01 |
システィミューン, インク. |
抗cd3抗体とその作製及び使用方法
|
WO2019060823A1
(en)
*
|
2017-09-22 |
2019-03-28 |
The Regents Of The University Of California |
INTERFÉRON-GAMMA MITIGATES ANTITUMOR IMMUNE RESPONSE TO A BLOCKING OF CONTROL POINTS
|
WO2019067682A1
(en)
*
|
2017-09-29 |
2019-04-04 |
Regeneron Pharmaceuticals, Inc. |
BISPECIFIC ANTIGEN-BINDING MOLECULES BINDING TO TARGET STAPHYLOCOCCUS ANTIGEN AND COMPONENT COMPONENT, AND USES THEREOF
|
US10927180B2
(en)
|
2017-10-13 |
2021-02-23 |
Harpoon Therapeutics, Inc. |
B cell maturation antigen binding proteins
|
PE20201183A1
(es)
|
2017-10-13 |
2020-11-03 |
Harpoon Therapeutics Inc |
Proteinas trispecificas y metodos de uso
|
WO2019075405A1
(en)
|
2017-10-14 |
2019-04-18 |
Cytomx Therapeutics, Inc. |
ANTIBODIES, ACTIVISTIC ANTIBODIES, BISPECIFIC ANTIBODIES, AND BISPECIFICALLY ACTIVATED ANTIBODIES AND METHODS OF USE THEREOF
|
KR101973060B1
(ko)
*
|
2017-10-20 |
2019-04-26 |
주식회사 녹십자 |
항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물
|
CA3082383A1
(en)
|
2017-11-08 |
2019-05-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
US11319355B2
(en)
|
2017-12-19 |
2022-05-03 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
EA202091557A1
(ru)
|
2017-12-22 |
2020-11-18 |
Тенеобио, Инк. |
Антитела, содержащие только тяжелые цепи, которые связываются с cd22
|
MX2020006639A
(es)
|
2017-12-22 |
2020-09-14 |
Regeneron Pharma |
Sistema y metodo para caracterizar las impurezas de un producto farmaceutico.
|
KR20200115485A
(ko)
|
2018-01-31 |
2020-10-07 |
리제너론 파마슈티칼스 인코포레이티드 |
약물 생성물 불순물을 특성화하기 위한 시스템 및 방법
|
TWI786265B
(zh)
|
2018-02-02 |
2022-12-11 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
AR115360A1
(es)
|
2018-02-08 |
2021-01-13 |
Genentech Inc |
Moléculas de unión al antígeno y métodos de uso
|
EP3749360A1
(en)
|
2018-02-09 |
2020-12-16 |
Genmab A/S |
Pharmaceutical compositions comprising bispecific antibodies directed against cd3 and cd20 and their uses
|
CA3088906A1
(en)
|
2018-02-28 |
2019-09-06 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for identifying viral contaminants
|
EP4317959A3
(en)
|
2018-03-19 |
2024-03-27 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
US10982006B2
(en)
|
2018-04-04 |
2021-04-20 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
US11505595B2
(en)
|
2018-04-18 |
2022-11-22 |
Xencor, Inc. |
TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
|
JP2021521784A
(ja)
|
2018-04-18 |
2021-08-30 |
ゼンコア インコーポレイテッド |
IL−15/IL−15RaFc融合タンパク質とPD−1抗原結合ドメインを含むPD−1標的化ヘテロダイマー融合タンパク質およびそれらの使用
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
SG11202011270QA
(en)
*
|
2018-05-24 |
2020-12-30 |
Janssen Biotech Inc |
Anti-cd3 antibodies and uses thereof
|
CN110540593B
(zh)
*
|
2018-05-29 |
2022-05-17 |
上海药明生物技术有限公司 |
新型的抗cd3/抗cd20双特异性抗体
|
WO2019246312A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
US20230009902A1
(en)
|
2018-06-20 |
2023-01-12 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue orginating from the endoderm
|
KR20210023982A
(ko)
|
2018-06-21 |
2021-03-04 |
리제너론 파아마슈티컬스, 인크. |
이중특이적 항-psma x 항-cd28 항체 및 이의 용도
|
CN112423785A
(zh)
*
|
2018-07-19 |
2021-02-26 |
瑞泽恩制药公司 |
双特异性抗BCMAx抗CD3抗体及其用途
|
BR112021003023A2
(pt)
*
|
2018-08-23 |
2021-05-11 |
Regeneron Pharmaceuticals, Inc. |
anticorpos anti-fc epsilon-r1 alfa (fcer1a), moléculas biespecíficas de ligação ao antígeno que ligam fcer1a e cd3, e usos dos mesmos
|
BR112020024296A2
(pt)
|
2018-08-27 |
2021-03-09 |
Regeneron Pharmaceuticals, Inc. |
Métodos para produção de um intermediário de purificação de proteína concentrado, para monitoramento e controle dos atributos de qualidade críticos em um intermediário de purificação de proteína e para monitorar e controlar os níveis de excipientes no fluido de cultura de células colhido e/ou intermediário de purificação de proteína, e, intermediário de purificação de proteína
|
SG11202011969WA
(en)
|
2018-08-30 |
2020-12-30 |
Regeneron Pharma |
Methods for characterizing protein complexes
|
CA3110513A1
(en)
*
|
2018-08-31 |
2020-03-05 |
Regeneron Pharmaceuticals, Inc. |
Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
|
IL297931A
(en)
|
2018-09-25 |
2023-01-01 |
Harpoon Therapeutics Inc |
dll3 binding proteins and methods of use
|
WO2020072821A2
(en)
|
2018-10-03 |
2020-04-09 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
KR20210111243A
(ko)
|
2018-10-31 |
2021-09-10 |
리제너론 파아마슈티컬스, 인크. |
단백질을 식별 및 정량화하는 방법 및 시스템
|
KR20210095165A
(ko)
|
2018-11-19 |
2021-07-30 |
프로제너티, 인크. |
바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
|
US11249089B2
(en)
|
2018-12-12 |
2022-02-15 |
Regeneron Pharmaceuticals, Inc. |
System and method of analysis of a protein using liquid chromatography-mass spectrometry
|
BR112021010238A2
(pt)
|
2018-12-19 |
2021-08-24 |
Regeneron Pharmaceuticals, Inc. |
Anticorpos anti-cd28 x anti-cd22 biespecíficos e usos dos mesmos
|
WO2020132024A1
(en)
|
2018-12-19 |
2020-06-25 |
Regeneron Pharmaceuticals, Inc. |
Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof
|
EA202191841A1
(ru)
|
2019-01-16 |
2021-10-07 |
Ридженерон Фармасьютикалз, Инк. |
Способы для идентификации свободных тиолов в белках
|
EP3917579A4
(en)
*
|
2019-01-28 |
2023-03-29 |
AB Therapeutics, Inc. |
SPECIFIC ANTIBODIES AND USES THEREOF
|
US20220106398A1
(en)
*
|
2019-02-08 |
2022-04-07 |
Igm Biosciences, Inc. |
Anti-gitr antigen-binding domains and uses thereof
|
US20220153819A1
(en)
|
2019-02-12 |
2022-05-19 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for using bispecific antibodies to bind complement and a target antigen
|
KR102527315B1
(ko)
*
|
2019-02-25 |
2023-05-03 |
주식회사 파멥신 |
항-Ang2 항체 및 이의 용도
|
SG11202109406TA
(en)
|
2019-03-01 |
2021-09-29 |
Xencor Inc |
Heterodimeric antibodies that bind enpp3 and cd3
|
CA3126728A1
(en)
*
|
2019-03-08 |
2020-09-17 |
Genentech, Inc. |
Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles
|
CN113661177B
(zh)
|
2019-03-22 |
2024-04-16 |
里珍纳龙药品有限公司 |
EGFR x CD28多特异性抗体
|
TW202039578A
(zh)
|
2019-03-29 |
2020-11-01 |
荷蘭商美勒斯公司 |
Cd3結合分子
|
JP2022527541A
(ja)
*
|
2019-04-04 |
2022-06-02 |
ヤンセン バイオテツク,インコーポレーテツド |
抗hla-c抗体及びその使用
|
US11613576B2
(en)
|
2019-04-09 |
2023-03-28 |
Sanofi |
Trispecific binding proteins, methods, and uses thereof
|
KR20220007586A
(ko)
|
2019-05-13 |
2022-01-18 |
리제너론 파마슈티칼스 인코포레이티드 |
개선된 경쟁적 리간드 결합 검정
|
WO2020232247A1
(en)
|
2019-05-14 |
2020-11-19 |
Provention Bio, Inc. |
Methods and compositions for preventing type 1 diabetes
|
KR20220035368A
(ko)
*
|
2019-06-07 |
2022-03-22 |
아디맵 엘엘씨 |
조작된 ph-의존성 항-cd3 항체, 및 이의 생성 및 사용 방법
|
TW202108628A
(zh)
|
2019-06-14 |
2021-03-01 |
美商泰尼歐生物公司 |
與c d 2 2 及c d 3 結合之多特異性重鏈抗體
|
CN112111012B
(zh)
*
|
2019-06-20 |
2023-07-04 |
成都恩沐生物科技有限公司 |
共价多特异性抗体
|
CN114025802B
(zh)
|
2019-06-21 |
2024-04-23 |
瑞泽恩制药公司 |
结合psma和cd3的双特异性抗原结合分子与4-1bb共刺激组合的用途
|
DE102019121007A1
(de)
|
2019-08-02 |
2021-02-04 |
Immatics Biotechnologies Gmbh |
Antigenbindende Proteine, die spezifisch an MAGE-A binden
|
BR112022002653A2
(pt)
|
2019-08-15 |
2022-05-03 |
Genmab As |
Composição farmacêutica, uso da composição farmacêutica, métodos para tratar câncer, para preparar uma composição farmacêutica e para preparar uma forma de dosagem unitária, forma de dosagem unitária, recipiente, e, kit de partes
|
CA3147791A1
(en)
*
|
2019-08-15 |
2021-02-18 |
Lauric Haber |
Multispecific antigen-binding molecules for cell targeting and uses thereof
|
CN112390882A
(zh)
*
|
2019-08-19 |
2021-02-23 |
杨洋 |
靶向cd3和cd20的双特异性抗体及其应用
|
RU2738802C1
(ru)
*
|
2019-08-21 |
2020-12-17 |
Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" |
Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула
|
US20220323937A1
(en)
|
2019-09-24 |
2022-10-13 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for chromatography use and regeneration
|
IL293112A
(en)
|
2019-11-25 |
2022-07-01 |
Regeneron Pharma |
Sustained release formulations using non-aqueous emulsions
|
TW202128744A
(zh)
|
2019-12-06 |
2021-08-01 |
美商再生元醫藥公司 |
抗vegf蛋白組合物及其製備方法
|
MX2022006714A
(es)
|
2019-12-06 |
2022-08-08 |
Regeneron Pharma |
Métodos de tratamiento del mieloma múltiple con anticuerpos anti-bcma x anti-cd3 bisespecíficos.
|
TW202135860A
(zh)
|
2019-12-10 |
2021-10-01 |
美商再生元醫藥公司 |
含有抗cd20x抗cd3雙特異性抗體之穩定調配物
|
GB201918230D0
(en)
|
2019-12-11 |
2020-01-22 |
Prec Therapeutics Ltd |
Antibodies and their uses
|
CN115666704A
(zh)
|
2019-12-13 |
2023-01-31 |
比奥拉治疗股份有限公司 |
用于将治疗剂递送至胃肠道的可摄取装置
|
KR20220113790A
(ko)
|
2019-12-13 |
2022-08-16 |
제넨테크, 인크. |
항-ly6g6d 항체 및 사용 방법
|
KR20230088853A
(ko)
|
2020-01-21 |
2023-06-20 |
리제너론 파마슈티칼스 인코포레이티드 |
당질화된 단백질의 전기영동을 위한 탈당질화 방법
|
KR20210095781A
(ko)
|
2020-01-24 |
2021-08-03 |
주식회사 에이프릴바이오 |
항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
|
JP2023527609A
(ja)
|
2020-02-21 |
2023-06-30 |
ハープーン セラピューティクス,インク. |
Flt3結合タンパク質および使用方法
|
CN113563473A
(zh)
|
2020-04-29 |
2021-10-29 |
三生国健药业(上海)股份有限公司 |
四价双特异性抗体、其制备方法和用途
|
US20230203161A1
(en)
|
2020-04-29 |
2023-06-29 |
Teneobio, Inc |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
JP2023524062A
(ja)
|
2020-05-01 |
2023-06-08 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
治療用タンパク質に対する中和抗体アッセイ
|
MX2022013797A
(es)
|
2020-05-08 |
2022-11-30 |
Genmab As |
Anticuerpos biespecificos contra cd3 y cd20.
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
US12006366B2
(en)
|
2020-06-11 |
2024-06-11 |
Provention Bio, Inc. |
Methods and compositions for preventing type 1 diabetes
|
CN115916825A
(zh)
|
2020-06-19 |
2023-04-04 |
豪夫迈·罗氏有限公司 |
与cd3和cd19结合的抗体
|
IL300666A
(en)
|
2020-08-19 |
2023-04-01 |
Xencor Inc |
ANTI–CD28 COMPOSITIONS
|
CN112062855A
(zh)
*
|
2020-08-26 |
2020-12-11 |
康诺亚生物医药科技(成都)有限公司 |
一种含有衔接器的药物治疗剂的开发和应用
|
MX2023002417A
(es)
|
2020-08-31 |
2023-03-22 |
Regeneron Pharma |
Estrategias de suministro de asparagina para mejorar el rendimiento del cultivo celular y mitigar las variantes de secuencia de asparagina.
|
CA3190349A1
(en)
|
2020-09-10 |
2022-03-17 |
Brian Elliott |
Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
|
CA3189883A1
(en)
|
2020-09-10 |
2022-03-17 |
Brian Elliott |
Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
|
IL301085A
(en)
|
2020-09-10 |
2023-05-01 |
Genmab As |
A bispecific antibody against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
|
BR112023004351A2
(pt)
|
2020-09-10 |
2023-04-04 |
Genmab As |
Método para tratar linfoma folicular em um sujeito humano
|
KR20230066581A
(ko)
|
2020-09-10 |
2023-05-16 |
젠맵 에이/에스 |
미만성 대 b-세포 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
|
IL301242A
(en)
*
|
2020-09-11 |
2023-05-01 |
Janssen Biotech Inc |
Multispecific vaccine targeting molecules and their uses
|
MX2023003214A
(es)
|
2020-09-18 |
2023-05-24 |
Regeneron Pharma |
Moleculas de union al antigeno que se unen a cd38 y/o cd28 y usos de las mismas.
|
WO2022072762A1
(en)
|
2020-10-02 |
2022-04-07 |
Regeneron Pharmaceuticals, Inc. |
Combination of antibodies for treating cancer with reduced cytokine release syndrome
|
US20220160828A1
(en)
|
2020-11-25 |
2022-05-26 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous membrane emulsification
|
MX2023007225A
(es)
|
2020-12-17 |
2023-06-27 |
Regeneron Pharma |
Fabricacion de microgeles encapsuladores de proteina.
|
JP2024503408A
(ja)
|
2021-01-20 |
2024-01-25 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
細胞培養におけるタンパク質力価の改善方法
|
KR20230157315A
(ko)
|
2021-01-28 |
2023-11-16 |
리제너론 파마슈티칼스 인코포레이티드 |
사이토카인 방출 증후군을 치료하기 위한 조성물 및 방법
|
BR112023017442A2
(pt)
|
2021-03-03 |
2023-09-26 |
Regeneron Pharma |
Métodos para identificar regiões em uma proteína e para modificar a viscosidade de uma droga proteica, e, droga proteica
|
CN117157319A
(zh)
|
2021-03-09 |
2023-12-01 |
Xencor股份有限公司 |
结合cd3和cldn6的异二聚抗体
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Cd3及びgpc3に結合するヘテロ二量体抗体
|
BR112023018665A2
(pt)
|
2021-03-26 |
2023-10-03 |
Regeneron Pharma |
Métodos e sistemas para desenvolvimento de protocolos de mistura
|
AU2021443863A1
(en)
|
2021-04-30 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
TW202243689A
(zh)
|
2021-04-30 |
2022-11-16 |
瑞士商赫孚孟拉羅股份公司 |
抗cd20/抗cd3雙特異性抗體及抗cd78b抗體藥物結合物的組合治療之給藥
|
TW202314240A
(zh)
|
2021-06-01 |
2023-04-01 |
美商再生元醫藥公司 |
微晶片毛細管電泳分析及試劑
|
EP4355778A1
(en)
|
2021-06-17 |
2024-04-24 |
Boehringer Ingelheim International GmbH |
Novel tri-specific binding molecules
|
WO2022266660A1
(en)
*
|
2021-06-17 |
2022-12-22 |
Amberstone Biosciences, Inc. |
Anti-cd3 constructs and uses thereof
|
WO2023028612A2
(en)
|
2021-08-27 |
2023-03-02 |
Board Of Regents, The University Of Texas System |
Anti-tslpr (crlf2) antibodies
|
US20230077710A1
(en)
|
2021-09-08 |
2023-03-16 |
Regeneron Pharmaceuticals, Inc. |
HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
|
CA3232463A1
(en)
|
2021-09-20 |
2023-03-23 |
Philip Mellors |
Methods of controlling antibody heterogeneity
|
CA3230246A1
(en)
*
|
2021-09-30 |
2023-04-06 |
Wenxin Xu |
Bispecific antibody and use thereof
|
CA3230985A1
(en)
|
2021-10-07 |
2023-04-13 |
Ross BROWNE |
Ph meter calibration and correction
|
AU2022360838A1
(en)
|
2021-10-07 |
2024-03-28 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods of ph modeling and control
|
CA3236367A1
(en)
|
2021-10-26 |
2023-05-04 |
Michelle Lafond |
Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
|
CA3234825A1
(en)
|
2021-10-28 |
2023-05-04 |
Lyell Immunopharma, Inc. |
Methods of generating cells
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023138551A1
(zh)
*
|
2022-01-20 |
2023-07-27 |
上海君实生物医药科技股份有限公司 |
抗cd3和抗cd20双特异性抗体及其用途
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
US20230296559A1
(en)
|
2022-03-18 |
2023-09-21 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for analyzing polypeptide variants
|
TW202346356A
(zh)
*
|
2022-03-23 |
2023-12-01 |
大陸商上海濟煜醫藥科技有限公司 |
抗cd3抗體、其製備方法及應用
|
US20230414750A1
(en)
|
2022-03-23 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
TW202346337A
(zh)
|
2022-03-29 |
2023-12-01 |
美商恩格姆生物製藥公司 |
Ilt3及cd3結合劑以及其使用方法
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
US20230357446A1
(en)
|
2022-04-11 |
2023-11-09 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for universal tumor cell killing
|
TW202404637A
(zh)
|
2022-04-13 |
2024-02-01 |
瑞士商赫孚孟拉羅股份公司 |
抗cd20/抗cd3雙特異性抗體之醫藥組成物及使用方法
|
WO2023198839A2
(en)
|
2022-04-13 |
2023-10-19 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20
|
WO2023214960A1
(en)
|
2022-05-02 |
2023-11-09 |
Regeneron Pharmaceuticals, Inc. |
Biochemical assays for therapeutic proteins
|
US20230416396A1
(en)
|
2022-05-18 |
2023-12-28 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof
|
WO2023235805A2
(en)
*
|
2022-06-01 |
2023-12-07 |
The Wistar Institute Of Anatomy And Biology |
Dna-encoded bispecific antibodies targeting carbonic anhydrase 9 and methods of use in cancer therapeutics
|
WO2024012513A1
(en)
*
|
2022-07-13 |
2024-01-18 |
Hansoh Bio Llc |
Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
|
US20240043560A1
(en)
|
2022-08-02 |
2024-02-08 |
Regeneron Pharmaceuticals, Inc. |
Methods of Treating Metastatic Castration-Resistant Prostate Cancer with Bispecific Anti-PSMA x Anti-CD28 Antibodies in Combination with Anti-PD-1 Antibodies
|
WO2024044655A1
(en)
|
2022-08-24 |
2024-02-29 |
Sana Biotechnology, Inc. |
Delivery of heterologous proteins
|
WO2024077174A1
(en)
|
2022-10-05 |
2024-04-11 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells
|
WO2024088987A1
(en)
|
2022-10-26 |
2024-05-02 |
F. Hoffmann-La Roche Ag |
Combination therapy for the treatment of cancer
|
CN116023499B
(zh)
*
|
2022-10-26 |
2024-01-23 |
北京力邦生物医药科技有限公司 |
一种针对cd3和cd20的双特异性抗体
|
WO2024119157A1
(en)
|
2022-12-02 |
2024-06-06 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|
WO2024123698A1
(en)
|
2022-12-08 |
2024-06-13 |
Regeneron Pharmaceuticals, Inc. |
Methods to characterizing a fragment crystallizable domain of a bispecific antibody
|
US20240198253A1
(en)
|
2022-12-16 |
2024-06-20 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for assessing chromatographic column integrity
|